G. Schulze

Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.

S. Lenk, S. Loening, H. Schlechte, 2005, Anticancer research.

Tumor M2 Pyruvate Kinase in Plasma of Patients with Urological Tumors

S. Loening, K. Jung, D. Schnorr, 2001, Tumor Biology.

Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.

J. Schneider, G. Schulze, 2003, Anticancer research.

The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.

G. Schulze, 2000, Anticancer research.

First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany

H. Stein, H. Ellerbrok, G. Pauli, 1999, Leukemia.

TP53 Gene in Blood Plasma DNA of Tumor Patients

H. Schlechte, M. Fleischhacker, S. Weickmann, 2004, Annals of the New York Academy of Sciences.

Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor‐α and melphalan

P. Schlag, P. Hohenberger, C. Kettelhack, 2000, Critical care medicine.

Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.

Joachim Schneider, Norman Bitterlich, N. Bitterlich, 2005, Anticancer research.